How we approach suppressive antibiotic therapy (SAT) following debridement, antibiotics, and implant retention for prosthetic joint infection

Authors/contributors
Abstract
Abstract The optimal treatment of prosthetic joint infection (PJI) remains uncertain. Patients undergoing debridement and implant retention (DAIR) receive extended antimicrobial treatment, and some experts leave patients at perceived highest risk of relapse on suppressive antibiotic therapy (SAT). In this narrative review, we synthesize the literature concerning the role of SAT to prevent treatment failure following DAIR, attempting to answer three key questions: 1) What factors identify patients at highest risk for treatment failure after DAIR (i.e. patients with the greatest potential to benefit from SAT)? 2) Does SAT reduce the rate of treatment failure after DAIR? And 3) What are the rates of treatment failure and adverse events necessitating treatment discontinuation in patients receiving SAT? We conclude by proposing risk-benefit stratification criteria to guide use of SAT after DAIR for PJI, informed by the limited available literature.
Publication
Clinical Infectious Diseases
Date
2023-08-17
Citation
1.
Cortes-Penfield N, Krsak M, Damioli L, et al. How we approach suppressive antibiotic therapy (SAT) following debridement, antibiotics, and implant retention for prosthetic joint infection. Clinical Infectious Diseases. Published online August 17, 2023:ciad484.